Measles
Last Updated: 2019-08-27
ICD11: -
Last Updated: 2019-08-27
Author(s): Anzengruber F., Navarini A.
ICD11: -
Morbilli, first infectious disease.
After a measles infection has already occurred, a lifelong immunity exists.
Antipyretic measures, e.g:
Topical therapy
Vaccination against |
Category | Indication | Application notes |
Measles | S |
Persons born after 1970 ≥ 18 years old with unclear vaccination status, without vaccination or with only one vaccination in childhood |
Single vaccination with an MMR vaccine |
I |
When admission is imminent or when visiting a community institution (e.g. day care centre): Infants aged 9 months and over |
Double vaccination with one MMR/V-*vaccine If the first vaccination takes place at the age of 9 - 10 months, the 2nd MMR/V vaccination should already be given at the beginning of the 2nd year of life. |
|
I |
Born after 1970 from the age of 9 months with unclear vaccination status, without vaccination or with only one vaccination in childhood
exceptionally 6 - 8-month-old infants after individual risk-benefit analysis (off-label use) |
Single MMR(V)-**vaccination If necessary, complete in accordance with the recommendations applicable to the age group. If the first vaccination takes place at the age of 9 - 10 months, the 2nd MMR/V* vaccination should already be given at the beginning of the 2nd year of life. For first vaccination at the age of 6 - 8 months, a 2nd and 3rd MMR/V* vaccination should be given at the age of 11 - 14 and 15 - 23 months. * MMR/V = MMRV or MMR in co-administration with VZV vaccine ** MMR(V) = MMR with or without co-administration of VZV vaccine |
|
B |
Health services or care for immunodeficient or immunocompromised persons or persons working in community institutions: after 1970 Gebo-rene with unclear vaccination status, without vaccination or with only one vaccination in childhood. |
Single vaccination with an MMR vaccine |
S: Standard vaccinations with general use
I: Indication vaccinations for risk groups with individually (not occupational) increased exposure, disease or complication risk as well as for the protection of third parties
B: Vaccinations due to an increased occupational risk, e.g. after risk assessment in accordance with the Occupational Health and Safety Act/Biostuffs Ordinance/Ordinance on Occupational Health and Safety (ArbMedVV) and/or for the protection of third parties within the scope of the occupational activity
Robert Koch Institute, Epidemiological Bulletin No. 34. (2015).Rki.de.Retrieved 10 May 2016, from https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/34_15.pdf?__blob=publicationFile
Adverse side effects after MMR vaccination per 1 million vaccinated persons |
Complications of measles per 1 million measles sufferers |
|
Immunodeficiency | Very rare | All patients |
Ear infection |
0 | 70000-90000 |
Pneumonia | 0 | 10000-60000 |
Hospitalisation | 20-50 | 10000-25000 |
Febrile convulsions | 30-300 | 5000-7000 |
Brain inflammation | 0.6-1.6 | 200-2000 |
Platelet count | 30 | 330 |
Subacute sclerosing Panencephalitis (SSPE)* |
0 | 1-10 |
Allergic shock reaction (anaphylaxis) |
1-10 | 0 |
Autism | 0 | 0 |
Deaths |
< 1** | 300 bis 1000 |
Expenses |
1 million vaccinations cost 140 million francs. |
1 million patients cost between 3.6 and 5 billion Swiss francs. |
* The SSPE is a late consequence of a measles infection. Years after the infection, a creeping inflammation of the brain develops, which cannot be cured and is always fatal.
** No death is expected and no death due to the vaccine is known to date, but the risk cannot be completely ruled out.
Source: Federal Office of Public Health - Measles. (2016). Bag.admin.ch. Retrieved 10 May 2016, from http://www.bag.admin.ch/themen/medizin/00682/00684/01087/index.html lang=en
Share your experience and shape the future with us!
Do you have 5 minutes to take our short survey?
Together with you we would like to further develop DermaCompass.
There is the chance to win one of 3x50 EUR Amazon vouchers.
Be part of our innovation process!
Share your experience